Andrew Hirsch - 23 Feb 2022 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
President & CEO, Director
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
23 Feb 2022
Transactions value $
$0
Form type
4
Filing time
23 Feb 2022, 15:30:46 UTC
Previous filing
07 Jun 2021
Next filing
12 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Performance Restricted Stock Units Award $0 +87.5K $0.00 87.5K 23 Feb 2022 Common Stock 87.5K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 72,500 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones.